ArticleNeuron2020
mGlu
Open access · bronzeAbstract read
In one paragraph
Article in Neuron, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 76 citations in OpenAlex.
- Discovery of VU6066098: A Selective and CNS-Penetrant mGluACS chemical neuroscience · 2026Article
- Coadministration of scopolamine and mGlu2 NAM VU6001966 as a novel antidepressant approach: Lowering effective dose and reducing cognitive side effects.Psychopharmacology · 2026Article
- Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.Biomedicines · 2026Review
- Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.Frontiers in cell and developmental biology · 2026Review
- Gypenosides Attenuates CORT-Induced Ferroptosis via Inhibiting TNF-α/NF-κB Signaling Pathway in PC12 Cells.Molecules (Basel, Switzerland) · 2025Article
- Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2.ACS pharmacology & translational science · 2024Article
- Article
- Activation of Metabotropic Glutamate Receptor 3 Modulates Thalamo-accumbal Transmission and Rescues Schizophrenia-Like Physiological and Behavioral Deficits.Biological psychiatry · 2024Article
- mGluPharmacology, biochemistry, and behavior · 2024Article
- Acute alcohol and chronic drinking bidirectionally regulate the excitability of prefrontal cortex vasoactive intestinal peptide interneurons.Neuropharmacology · 2023Article
- mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.European archives of psychiatry and clinical neuroscience · 2023Review
- Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?Cellular and molecular neurobiology · 2023Review
- Acute alcohol and chronic drinking bidirectionally regulate the excitability of prefrontal cortex vasoactive intestinal peptide interneurons.bioRxiv : the preprint server for biology · 2023Article
- Sex differences and hormonal regulation of metabotropic glutamate receptor synaptic plasticity.International review of neurobiology · 2023Review
- Metabotropic glutamate receptor function and regulation of sleep-wake cycles.International review of neurobiology · 2023Article
- The role of thalamic group II mGlu receptors in health and disease.Neuronal signaling · 2022Review
- Adolescent sleep and the foundations of prefrontal cortical development and dysfunction.Progress in neurobiology · 2022Review
- Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.Pharmacology, biochemistry, and behavior · 2022Review
- Advances in translating mGluPharmacology, biochemistry, and behavior · 2022Review
- Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.Pharmacological reviews · 2022Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Max E JoffeDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN 37232, USA; Vanderbilt Center for Addiction Research, Nashville, TN 37232, USA. Electronic address: max.joffe@vanderbilt.edu.
Chiaki I SantiagoVanderbilt Center for Neuroscience Drug Discovery, Nashville, TN 37232, USA; Vanderbilt University, Nashville, TN 37232, USA.
Kendra H OliverDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.
James MaksymetzDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN 37232, USA.
Nicholas A HarrisVanderbilt Center for Addiction Research, Nashville, TN 37232, USA; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232, USA.
Julie L EngersVanderbilt Center for Neuroscience Drug Discovery, Nashville, TN 37232, USA.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN 37232, USA; Vanderbilt Center for Addiction Research, Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA.
Danny G WinderDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Addiction Research, Nashville, TN 37232, USA; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232, USA.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN 37232, USA; Vanderbilt Center for Addiction Research, Nashville, TN 37232, USA. Electronic address: jeff.conn@vanderbilt.edu.
Vanderbilt University · US
Funding
REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9MResearch Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1MFUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2MDiscovery of mGlu receptor PAMs for treatment of schizophreniaR01MH119673 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2019 to 2023
$3.6MFunctions of Metabotropic Glutamate Receptor SubtypesR37NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2014 to 2020
$3.5MPostdoctoral Training in CNS Drug Discovery ResearchT32MH093366 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2011 to 2015
$1.0MNICHD NIH HHS U54 HD083211NIMH NIH HHS R01 MH062646NIMH NIH HHS R01 MH119673NIMH NIH HHS T32 MH093366NINDS NIH HHS R01 NS031373NINDS NIH HHS R37 NS031373
Abstract
Non-selective antagonists of metabotropic glutamate receptor subtypes 2 (mGlu
Indexed as
Adaptation, PsychologicalAllosteric RegulationAnhedoniaAnimalsAntidepressive AgentsBehavior, AnimalCerebral CortexExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsGlutamic AcidLong-Term Synaptic DepressionMaleMiceMice, KnockoutMice, TransgenicNeural PathwaysAntidepressive AgentsExcitatory Amino Acid AgonistsExcitatory Amino Acid AntagonistsGlutamic Acidmetabotropic glutamate receptor 2metabotropic glutamate receptor 3Proto-Oncogene Proteins c-fosReceptors, Metabotropic Glutamateanhedoniaantidepressantchronic stressmajor depressive disordermetabotropic glutamate receptormGlu receptorneuronal ensemblesprefrontal cortexsynaptic plasticitythalamus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.